We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Assessment of the effect of the Aquamantys<sup>®</sup> system on local recurrence after hepatectomy for hepatocellular carcinoma through propensity score matching.
- Authors
Sui, M. H.; Wang, H. G.; Chen, M. Y.; Wan, T.; Hu, B. Y.; Pan, Y. W.; Li, H.; Cai, H. Y.; Cui, C.; Lu, S. C.
- Abstract
Objective: To assess the effect of the intraoperative application of the Aquamantys® system to treat the hepatic resection margin on local and overall recurrence of HCC. Methods: We retrospectively analyzed 101 patients admitted from November 2016 to June 2018 who underwent hepatectomy using the Aquamantys® as hemostatic device, who were matched with 101 patients (control group) using conventional hemostatic devices through PSM. Univariate and multivariate analyses of recurrence-free survival (RFS) and local recurrence-free survival (LRFS) were performed using the Cox proportional hazard model. Results: There were no significant differences in baseline data and surgical procedures between the two groups. The Aquamantys® group showed less blood loss (P = 0.005) and a lower blood transfusion rate (P = 0.036), while the incidences of postoperative complications of the two groups showed no difference (P = 0.266). OS rates of the Aquamantys® group and the control group were 82.6% and 84.2%, respectively (P = 0. 446), and RFS rates were 65.5% and 58.2%, respectively (P = 0.153), with no significant differences. The Aquamantys® group and the control group had two cases and 11 cases of local recurrence, respectively, with LRFS rates of 98% and 87.9%, respectively, in the follow-up period, corresponding to a significant difference (P = 0.011). Multivariate analysis showed that microvascular invasion (MVI), tumor diameter > 5 cm, and the control group were independent risk factors for LRFS. Conclusion: Our results indicate that application of the Aquamantys® system in hepatectomy can reduce local recurrence, but it can neither reduce overall recurrence nor improve OS.
- Publication
Clinical & Translational Oncology, 2019, Vol 21, Issue 12, p1634
- ISSN
1699-048X
- Publication type
Article
- DOI
10.1007/s12094-019-02092-0